advertisement
Abstract #3619 Published in IGR 4-2
A comparison of once-daily morning versus evening dosing of concomitant latanoprost/timolol
Konstas AGP; Nakos E; Tersis I; Lallos NA; Leech JN; Stewart WCAmerican Journal of Ophthalmology 2002; 133: 753-757
PURPOSE: To evaluate morning versus evening once daily concomitant latanoprost 0.005%/timolol maleate 0.5% therapy in ocular hypertensive or primary open-angle glaucoma patients. DESIGN: Prospective single-center double-masked crossover comparison. METHODS: Patients who responded to timolol maleate 0.5% given twice daily were randomized to either evening or morning dosing of concomitant latanoprost 0.005% and timolol maleate 0.5% therapy for seven weeks. Twenty-four hour diurnal curve intraocular pressure (IOP) testing was performed following each period. RESULTS: Thirty-six patients completed this study. There was a significant reduction at each time point in the 24-hour diurnal curve of both evening (17.1 ± 2.7 mmHg) and morning (17.3 ± 3.1 mmHg) dosed latanoprost/timolol maleate compared with timolol maleate given twice daily (21.1 ± 3.3 mmHg) (p < 0.0001). When the morning and evening dosing groups were compared directly, the 06:00 time point was statistically lower with evening dosing (16.4 ± 2.3 mmHg) versus morning dosing (17.9 ± 2.8 mmHg) (p = 0.01). Overall, a trend existed for greater daytime reduction with night-time dosing of the concomitant therapy, whereas morning dosing tended to give lower night-time pressures. There was a significantly lower mean range of diurnal pressure with evening (3.6 mmHg) versus morning (4.3 mmHg) dosing (p = 0.02). No differences in adverse events existed between the treated arms. CONCLUSIONS: This study suggests that latanoprost and timolol maleate, both given once daily in the morning or evening, effectively reduce the IOP for the 24-hour diurnal curve when compared with timolol maleate twice daily.
Dr. A.G.P. Konstas, University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
